FDAsafety guidance66% confidence
FDA Drug Competition Action Plan | Maximizing scientific and regulatory clarity with respect to complex generic drugs
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Complex generic products are typically harder to develop, which means that many complex products face less competition than other products, and therefore can be more expensive and less accessible to the patients who need them.
Supporting Context
- Therapeutic area
- Gastroenterology · H2 Antagonist
- Sub-indication
- General
Related signal: Lupin's Famotidine ANDA217432 Receives Abbreviated Approval from FDA